Teresa C. DeFrancesco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Teresa C. DeFrancesco has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
Bruce W. Keene
College of Veterinary Medicine, North Carolina State University Department of Clinical Sciences Raleigh, North Carolina
22 shared publications- Kathryn M. Meurs
Department of Veterinary Clinical Sciences, North Carolina State University, Raleigh, USA
17 shared publications Clarke E. Atkins
15 shared publicationsB.W. Keene
North Carolina State University College of Veterinary Medicine, 1060 William Moore Drive, Raleigh, NC, 27606, USA
10 shared publicationsC.E. Atkins
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1052 William Moore Drive, Raleigh, NC, 27606, USA
9 shared publications- Joshua A. Stern
College of Veterinary Medicine, North Carolina State University, Raleigh, NC
6 shared publications
Latest Publications
- 1 December 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (12) , 1-8
An artificial intelligence–enabled digital stethoscope demonstrates moderate murmur detection in dogs but not cats and unreliable arrhythmia classification in both species
Objective: To prospectively evaluate the diagnostic performance of an AI-enabled digital stethoscope in detecting cardiac murmurs and arrhythmias compared to fourth-year veterinary students and experienced clinicians. Methods: Dogs and cats presenting to a university teaching hospital were prospectively enrolled from August 1, 2025, through December 31, 2025. Each animal underwent cardiac auscultation at 4 thoracic sites with the use of an AI-enabled digital stethoscope (Core 500; EKO Health Inc), 6-lead ECG, and echocardiogram, if clinically indicated. Auscultation was performed by a cardiology resident, board-certified cardiologist, and fourth-year veterinary student. Results: The stethoscope demonstrated a sensitivity of 86.8%, specificity of 56.3%, and positive predictive value of 82.5% for murmur detection in dogs. There was no difference between the agreement of the AI stethoscope or students with a clinician (κ = 0.447). In cats, sensitivity was markedly lower (9.1%), with only 2 of 22 murmurs detected (κ = 0.081). The stethoscope demonstrated high sensitivity for atrial fibrillation (100%), but classified no dog as arrhythmia-free. Murmur grade was the only significant predictor of stethoscope murmur diagnosis, and high-grade murmurs (≥ 3) had significantly greater odds of detection (OR, 15.11). Conclusions: The AI-enabled stethoscope demonstrated moderate murmur detection performance in dogs, comparable to fourth-year veterinary students, but performed poorly in cats. Arrhythmia classification was unreliable in both species. Clinical Relevance: AI-enabled stethoscopes represent an emerging tool in veterinary medicine, but clinical validation is necessary before routine adoption. This study provides prospective performance data across small animals and examiner levels, identifying meaningful limitations regarding interpretation of this technology.
- 1 December 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (12) , 1-8
An artificial intelligence–enabled digital stethoscope demonstrates moderate murmur detection in dogs but not cats and unreliable arrhythmia classification in both species
Objective: To prospectively evaluate the diagnostic performance of an AI-enabled digital stethoscope in detecting cardiac murmurs and arrhythmias compared to fourth-year veterinary students and experienced clinicians. Methods: Dogs and cats presenting to a university teaching hospital were prospectively enrolled from August 1, 2025, through December 31, 2025. Each animal underwent cardiac auscultation at 4 thoracic sites with the use of an AI-enabled digital stethoscope (Core 500; EKO Health Inc), 6-lead ECG, and echocardiogram, if clinically indicated. Auscultation was performed by a cardiology resident, board-certified cardiologist, and fourth-year veterinary student. Results: The stethoscope demonstrated a sensitivity of 86.8%, specificity of 56.3%, and positive predictive value of 82.5% for murmur detection in dogs. There was no difference between the agreement of the AI stethoscope or students with a clinician (κ = 0.447). In cats, sensitivity was markedly lower (9.1%), with only 2 of 22 murmurs detected (κ = 0.081). The stethoscope demonstrated high sensitivity for atrial fibrillation (100%), but classified no dog as arrhythmia-free. Murmur grade was the only significant predictor of stethoscope murmur diagnosis, and high-grade murmurs (≥ 3) had significantly greater odds of detection (OR, 15.11). Conclusions: The AI-enabled stethoscope demonstrated moderate murmur detection performance in dogs, comparable to fourth-year veterinary students, but performed poorly in cats. Arrhythmia classification was unreliable in both species. Clinical Relevance: AI-enabled stethoscopes represent an emerging tool in veterinary medicine, but clinical validation is necessary before routine adoption. This study provides prospective performance data across small animals and examiner levels, identifying meaningful limitations regarding interpretation of this technology.
- 3 June 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (9) , 1-10
Preliminary investigation of T-wave peak-end interval and its ratio to QT interval in dogs with an echocardiographic phenotype of dilated cardiomyopathy and its possible correlation with left ventricular diameter and volume
Objective: The T-wave peak-end (TpTe) interval and its ratio to the QT interval (TpTe:QT) are ECG markers of myocardial repolarization dispersion. We hypothesized that these markers are associated with echocardiographic indices reflecting structural remodeling in dogs with the dilated cardiomyopathy (DCM) phenotype and are minimally influenced by heart rate (HR). Methods: A cross-sectional study was conducted in dogs with an echocardiographic subtype of DCM, excluding sighthound breeds, between July 2021 and June 2023. Dogs receiving antiarrhythmic drugs prior to the diagnostic ECG were excluded. Repolarization markers (QT interval, corrected QT interval using the Fridericia formula [QTc], TpTe interval, and TpTe:QT) were retrospectively evaluated from in-clinic ECGs and correlated with echocardiographic variables (left ventricular end-diastolic diameter normalized to body weight [LVEDDN], left ventricular end-systolic diameter normalized to body weight [LVESDN], end-diastolic volume, end-systolic volume [ESV], end-diastolic volume normalized to body surface area, ESV normalized to body surface area, fractional shortening, and ejection fraction). Results: Correlation analysis between repolarization markers and HR showed a significant moderate negative correlation for the QT interval, whereas QTc exhibited a weak positive correlation. The TpTe interval showed a weak negative correlation, and TpTe:QT demonstrated a negligible correlation with HR; however, neither association was statistically significant. The TpTe interval showed significant weak correlations with LVEDDN and LVESDN, whereas TpTe:QT showed significant weak to moderate correlations with LVEDDN, LVESDN, ESV, and ESV normalized to body surface area, even after adjustment for HR. In contrast, QT and QTc were not significantly associated with any echocardiographic variable. Conclusions: The TpTe interval and TpTe:QT might have been independent of HR and correlated with left ventricular diameter and volume. Clinical Relevance: The TpTe interval and TpTe:QT may serve as ECG repolarization markers reflecting myocardial structural remodeling in dogs with DCM.
- 3 June 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (9) , 1-10
Preliminary investigation of T-wave peak-end interval and its ratio to QT interval in dogs with an echocardiographic phenotype of dilated cardiomyopathy and its possible correlation with left ventricular diameter and volume
Objective: The T-wave peak-end (TpTe) interval and its ratio to the QT interval (TpTe:QT) are ECG markers of myocardial repolarization dispersion. We hypothesized that these markers are associated with echocardiographic indices reflecting structural remodeling in dogs with the dilated cardiomyopathy (DCM) phenotype and are minimally influenced by heart rate (HR). Methods: A cross-sectional study was conducted in dogs with an echocardiographic subtype of DCM, excluding sighthound breeds, between July 2021 and June 2023. Dogs receiving antiarrhythmic drugs prior to the diagnostic ECG were excluded. Repolarization markers (QT interval, corrected QT interval using the Fridericia formula [QTc], TpTe interval, and TpTe:QT) were retrospectively evaluated from in-clinic ECGs and correlated with echocardiographic variables (left ventricular end-diastolic diameter normalized to body weight [LVEDDN], left ventricular end-systolic diameter normalized to body weight [LVESDN], end-diastolic volume, end-systolic volume [ESV], end-diastolic volume normalized to body surface area, ESV normalized to body surface area, fractional shortening, and ejection fraction). Results: Correlation analysis between repolarization markers and HR showed a significant moderate negative correlation for the QT interval, whereas QTc exhibited a weak positive correlation. The TpTe interval showed a weak negative correlation, and TpTe:QT demonstrated a negligible correlation with HR; however, neither association was statistically significant. The TpTe interval showed significant weak correlations with LVEDDN and LVESDN, whereas TpTe:QT showed significant weak to moderate correlations with LVEDDN, LVESDN, ESV, and ESV normalized to body surface area, even after adjustment for HR. In contrast, QT and QTc were not significantly associated with any echocardiographic variable. Conclusions: The TpTe interval and TpTe:QT might have been independent of HR and correlated with left ventricular diameter and volume. Clinical Relevance: The TpTe interval and TpTe:QT may serve as ECG repolarization markers reflecting myocardial structural remodeling in dogs with DCM.
- Open Access
- 24 February 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (3) , 267-273
Population Pharmacokinetics of Sildenafil in Dogs With Naturally Occurring Pulmonary Hypertension
The pharmacokinetics of sildenafil are ill‐defined in dogs with naturally occurring pulmonary hypertension (PH). Because the plasma concentrations of sildenafil have not been reported for dogs with this disease, this study aimed to describe the population pharmacokinetics of sildenafil in a sample of dogs with PH. Twenty client‐owned dogs with spontaneous PH associated with diverse comorbidities and receiving orally administered sildenafil were enrolled in a prospective, open‐label, steady‐state population pharmacokinetic study. Dogs underwent a sparse‐sampling blood collection protocol after the morning dose of sildenafil. Plasma sildenafil concentrations were determined using high‐pressure liquid chromatography and mass spectrometry. Population pharmacokinetic analysis with nonlinear mixed effects modeling was performed, and selected covariates were evaluated in the model. Sildenafil was rapidly absorbed (absorption half‐life 1.1 h) but variable (CV 94%) and reached maximal plasma concentrations at 2.51 h. The estimated elimination half‐life was 2.9 h. However, substantial individual variability in pharmacokinetics of sildenafil was evident, unexplained by the covariates examined, and attributed primarily to the high variability in absorption. This finding supports the need for a large‐scale study to identify the source of this variability to better guide therapy in poor responders to initial therapy with this drug.
- 24 February 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (3) , 267-273
Open AccessPopulation Pharmacokinetics of Sildenafil in Dogs With Naturally Occurring Pulmonary Hypertension
The pharmacokinetics of sildenafil are ill‐defined in dogs with naturally occurring pulmonary hypertension (PH). Because the plasma concentrations of sildenafil have not been reported for dogs with this disease, this study aimed to describe the population pharmacokinetics of sildenafil in a sample of dogs with PH. Twenty client‐owned dogs with spontaneous PH associated with diverse comorbidities and receiving orally administered sildenafil were enrolled in a prospective, open‐label, steady‐state population pharmacokinetic study. Dogs underwent a sparse‐sampling blood collection protocol after the morning dose of sildenafil. Plasma sildenafil concentrations were determined using high‐pressure liquid chromatography and mass spectrometry. Population pharmacokinetic analysis with nonlinear mixed effects modeling was performed, and selected covariates were evaluated in the model. Sildenafil was rapidly absorbed (absorption half‐life 1.1 h) but variable (CV 94%) and reached maximal plasma concentrations at 2.51 h. The estimated elimination half‐life was 2.9 h. However, substantial individual variability in pharmacokinetics of sildenafil was evident, unexplained by the covariates examined, and attributed primarily to the high variability in absorption. This finding supports the need for a large‐scale study to identify the source of this variability to better guide therapy in poor responders to initial therapy with this drug.
- Open Access
- 12 June 2025
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 61, 20-28
Effect of trazodone on heart rate, heart rate variability, and QT-intervals in dogs
- 12 June 2025
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 61, 20-28
Open AccessEffect of trazodone on heart rate, heart rate variability, and QT-intervals in dogs
- Open Access
- 26 April 2024
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 65 (4) , 429-436
A survey of the use of ultrasound by small animal veterinary clinicians
This study aimed to determine the current use of ultrasound amongst small animal veterinarians. A total of 1216 small animal veterinary practitioners responded to an electronic survey that was administered through the Veterinary Information Network to all its members. Descriptive statistics were generated; limited inferential statistics were performed to examine specific relationships. Eighty-four percent of respondents had access to an ultrasound unit, and 86% of respondents reported using their unit multiple times per week. The most common uses were assistance with cystocentesis (93%) and abdominocentesis (71%), pregnancy diagnosis (69%), limited abdominal evaluation (63%), to aid in thoracocentesis (59%), and limited thoracic evaluation (52%). Eighty-nine percent of respondents received some formal training in ultrasound, most commonly from continuing education courses. Most respondents (52%) reported receiving <= 25 h of training. Additionally, 88% of respondents believed it was either extremely or very important for there to be ultrasound training for veterinary students prior to graduation. Based on this survey, most small animal practitioners commonly use ultrasound for limited examinations, being most confident in the sonographic evaluation and centesis of the bladder and for the detection and centesis of effusion in a body cavity. With most respondents having <= 25 h of training in ultrasound, typically obtained in postgraduate courses, an expansion in standardized basic ultrasound training within the veterinary curriculum may be warranted.
- 26 April 2024
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 65 (4) , 429-436
Open AccessA survey of the use of ultrasound by small animal veterinary clinicians
This study aimed to determine the current use of ultrasound amongst small animal veterinarians. A total of 1216 small animal veterinary practitioners responded to an electronic survey that was administered through the Veterinary Information Network to all its members. Descriptive statistics were generated; limited inferential statistics were performed to examine specific relationships. Eighty-four percent of respondents had access to an ultrasound unit, and 86% of respondents reported using their unit multiple times per week. The most common uses were assistance with cystocentesis (93%) and abdominocentesis (71%), pregnancy diagnosis (69%), limited abdominal evaluation (63%), to aid in thoracocentesis (59%), and limited thoracic evaluation (52%). Eighty-nine percent of respondents received some formal training in ultrasound, most commonly from continuing education courses. Most respondents (52%) reported receiving <= 25 h of training. Additionally, 88% of respondents believed it was either extremely or very important for there to be ultrasound training for veterinary students prior to graduation. Based on this survey, most small animal practitioners commonly use ultrasound for limited examinations, being most confident in the sonographic evaluation and centesis of the bladder and for the detection and centesis of effusion in a body cavity. With most respondents having <= 25 h of training in ultrasound, typically obtained in postgraduate courses, an expansion in standardized basic ultrasound training within the veterinary curriculum may be warranted.
- 15 December 2023
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 51, 188-194
Clinical outcome of idiopathic juvenile ventricular arrhythmias in 25 dogs
- 15 December 2023
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 51, 188-194
Clinical outcome of idiopathic juvenile ventricular arrhythmias in 25 dogs
- Open Access
Evaluation of Renin–Angiotensin–Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine
Background: Chronic renin–angiotensin–aldosterone system (RAAS) activation is harmful. Amlodipine activates RAAS in humans and dogs, but contradictory data exist for systemically hypertensive (SHT) cats. Hypothesis: Cats with SHT and chronic kidney disease treated with amlodipine (SHT/CKD-A) are RAAS activated. Animals: Client-owned cats: unmedicated normotensive (NT) cats (n = 9); SHT/CKD-A cats (n = 5) with median systolic blood pressure of 170 mmHg (vs. 195 mmHg, pre-treatment), chronic kidney disease, and receiving no RAAS-suppressive therapy. Methods: Serum was frozen (−80 °C) until RAAS analysis via equilibrium analysis. The RAAS variables (reported as median (minimum–maximum)) were compared between groups, using Mann–Whitney U test. Results: Angiotensin 1, angiotensin 1,7, angiotensin III, and angiotensin 1,5, and angiotensin-converting enzyme (ACE)-2 activity were higher in SHT/CKD-A cats compared to NT cats, while ACE activity was lower in SHT/CKD-A cats compared to NT cats (p < 0.05 all). A marker for alternative RAAS influence (ALT-S) was significantly higher (69; 58–73 pmol/pmol) in SHT/CKD-A cats compared to NT cats (35; 14–63 pmol/pmol; p = 0.001). Aldosterone concentrations were significantly higher (393; 137–564 pmol/L) in SHT/CKD-A cats compared to NT cats (129; 28–206 pmol/L; p = 0.007). Conclusion and Clinical Importance: Circulating RAAS is activated in systemically hypertensive cats receiving amlodipine. Although this study did not parse out the individual contributions of SHT, chronic kidney disease, and amlodipine, the findings suggest that the use of concurrent RAAS-suppressant therapy, specifically aldosterone antagonism, in amlodipine-treated SHT cats with chronic kidney disease might be indicated.
Open AccessEvaluation of Renin–Angiotensin–Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine
Background: Chronic renin–angiotensin–aldosterone system (RAAS) activation is harmful. Amlodipine activates RAAS in humans and dogs, but contradictory data exist for systemically hypertensive (SHT) cats. Hypothesis: Cats with SHT and chronic kidney disease treated with amlodipine (SHT/CKD-A) are RAAS activated. Animals: Client-owned cats: unmedicated normotensive (NT) cats (n = 9); SHT/CKD-A cats (n = 5) with median systolic blood pressure of 170 mmHg (vs. 195 mmHg, pre-treatment), chronic kidney disease, and receiving no RAAS-suppressive therapy. Methods: Serum was frozen (−80 °C) until RAAS analysis via equilibrium analysis. The RAAS variables (reported as median (minimum–maximum)) were compared between groups, using Mann–Whitney U test. Results: Angiotensin 1, angiotensin 1,7, angiotensin III, and angiotensin 1,5, and angiotensin-converting enzyme (ACE)-2 activity were higher in SHT/CKD-A cats compared to NT cats, while ACE activity was lower in SHT/CKD-A cats compared to NT cats (p < 0.05 all). A marker for alternative RAAS influence (ALT-S) was significantly higher (69; 58–73 pmol/pmol) in SHT/CKD-A cats compared to NT cats (35; 14–63 pmol/pmol; p = 0.001). Aldosterone concentrations were significantly higher (393; 137–564 pmol/L) in SHT/CKD-A cats compared to NT cats (129; 28–206 pmol/L; p = 0.007). Conclusion and Clinical Importance: Circulating RAAS is activated in systemically hypertensive cats receiving amlodipine. Although this study did not parse out the individual contributions of SHT, chronic kidney disease, and amlodipine, the findings suggest that the use of concurrent RAAS-suppressant therapy, specifically aldosterone antagonism, in amlodipine-treated SHT cats with chronic kidney disease might be indicated.
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (6) , 2003-2010
Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
Background: Pimobendan is an important therapy for dogs with myxomatous mitral valve disease (MMVD). The pharmacokinetics are reported in healthy dogs but not in dogs with heart disease. Hypothesis/Objectives: To determine if dog characteristics such as age, breed, body condition score, ACVIM stage of heart disease or biochemical laboratory value alter the pharmacokinetics of orally administered pimobendan and its metabolite in a cohort of dogs with naturally occurring MMVD. Animals: Fifty-seven client-owned dogs with MMVD ACVIM Stage B2, C, or D and administered pimobendan to steady state blood concentrations. Methods: Prospective, observational study. Samples were collected using a sparse-sampling protocol at specific intervals after administration of pimobendan. Plasma pimobendan and the active metabolite (O-desmethyl-pimobendan, ODMP) concentrations were determined via high-pressure liquid chromatography and fluorescence detection. Data was analyzed via a population pharmacokinetic approach and nonlinear mixed effects modeling (NLME). Numerous covariates were examined in the NLME model. Results: The absorption and elimination half-lives (t1/2) were approximately 1.4 and 1 hour for pimobendan and 1.4 and 1.3 hours for ODMP, respectively. Pharmacokinetic parameters were highly variable, especially the values for pimobendan absorption and elimination rate, and absorption rate of ODMP with coefficients of variation of 147.84%, 64.51% and 64.49%, respectively. No covariate evaluated was a significant source of variability. Conclusions and Clinical Importance: The pharmacokinetic parameters were highly variable among this group of dogs with MMVD. The variability was not associated with the dog's age, body weight or condition score, stage of heart disease, dose, serum creatinine, or alkaline phosphatase.
- 1 November 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (6) , 2003-2010
Open AccessPharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
Background: Pimobendan is an important therapy for dogs with myxomatous mitral valve disease (MMVD). The pharmacokinetics are reported in healthy dogs but not in dogs with heart disease. Hypothesis/Objectives: To determine if dog characteristics such as age, breed, body condition score, ACVIM stage of heart disease or biochemical laboratory value alter the pharmacokinetics of orally administered pimobendan and its metabolite in a cohort of dogs with naturally occurring MMVD. Animals: Fifty-seven client-owned dogs with MMVD ACVIM Stage B2, C, or D and administered pimobendan to steady state blood concentrations. Methods: Prospective, observational study. Samples were collected using a sparse-sampling protocol at specific intervals after administration of pimobendan. Plasma pimobendan and the active metabolite (O-desmethyl-pimobendan, ODMP) concentrations were determined via high-pressure liquid chromatography and fluorescence detection. Data was analyzed via a population pharmacokinetic approach and nonlinear mixed effects modeling (NLME). Numerous covariates were examined in the NLME model. Results: The absorption and elimination half-lives (t1/2) were approximately 1.4 and 1 hour for pimobendan and 1.4 and 1.3 hours for ODMP, respectively. Pharmacokinetic parameters were highly variable, especially the values for pimobendan absorption and elimination rate, and absorption rate of ODMP with coefficients of variation of 147.84%, 64.51% and 64.49%, respectively. No covariate evaluated was a significant source of variability. Conclusions and Clinical Importance: The pharmacokinetic parameters were highly variable among this group of dogs with MMVD. The variability was not associated with the dog's age, body weight or condition score, stage of heart disease, dose, serum creatinine, or alkaline phosphatase.
- 28 June 2023
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 49, 9-28
Pacemaker-lead-associated thrombosis in dogs: a multicenter retrospective study
- 28 June 2023
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 49, 9-28
Pacemaker-lead-associated thrombosis in dogs: a multicenter retrospective study